Briefly, patients with objective responses (complete or partial), or stable disease with tumor shrinkage and PFS of at least 6 months, were classified as having clinical benefit (CB). Patients with progressive disease and PFS less than 3 months were classified as having no clinical benefit (NCB). All other patients were classified as having intermediate clinical benefit (ICB).
CB组：CR，PR，PD且PFS>6
NCB : PD且PFS<3
ICB：其他
参考文献：Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
